AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01474473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot
Description: The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days
Study NCT01474473 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Nonremovable, Windowed, Fiberglass Cast Boot
Description: The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days
Study NCT00098137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Study NCT00098137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan
Study NCT04012593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diary
Study NCT00952068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid® OAD 200mg
Description: 1 Tramadol Contramid® OAD 200mg tablet daily.
Study NCT01659593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procog
Description: 3 to 5 people group program
Study NCT03683485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long duration EPBD
Description: An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
Study NCT03683485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long duration EPBD
Description: An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
Study NCT03683485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST
Description: After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
Study NCT03683485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EST
Description: After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
Study NCT04212091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm
Study NCT01659593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01453088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).
Study NCT01453088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.
Study NCT02248753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Study NCT02248753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT02248753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02248753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological cardioversion - Amiodarone
Study NCT00791102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP-1001 nasal spray
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Study NCT04212091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered via IV infusion or SC infusion, depending on the arm
Study NCT02132299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
Study NCT02132299 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Study NCT02132299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
Study NCT01503632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive intervention program
Study NCT01503632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Correlative studies
Study NCT01503632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Monitoring
Description: Correlative studies
Study NCT01503632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01503632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01503632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally
Study NCT01503632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given orally
Study NCT01503632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02132299 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
Study NCT01093742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Subcutaneously administrate at 0 hour on Day 1
Study NCT01093742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01503632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01503632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Receive usual standard of care
Study NCT02519348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Study NCT00791102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ASP-1001
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Study NCT01984853 — intervention group
Intervention type: OTHER
Intervention: OBSERVATIONAL REGISTRY
Study NCT04397614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Assessments
Description: Daily symptom tracker
Study NCT04480723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood samples will be taken and analyzed to evaluate the presence of PH.
Study NCT04480723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI will be performed to evaluate the presence of PH.
Study NCT02397681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Testing
Description: Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
Study NCT03555708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
Study NCT02519348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Study NCT02519348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The WISC-V
Description: The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
Study NCT05473949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Description: Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The NEPSY-II
Description: The NEPSY-II (Korkman et al., 2012). The Narrative Memory subtest is designed to assess verbal memory using organised language material.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The Child Executive Function Evaluation Battery CEF
Description: The Child Executive Function Evaluation Battery CEF (Roy et al., 2021), which aims to evaluate the four main components of executive function (inhibition, working memory, flexibility and planning).
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The CONNERS 3 long version
Description: The  CONNERS 3 long version  (Conners, 2008), which assesses attentional skills by means of a questionnaire to be completed by parents.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The BRIEF
Description: The 'BRIEF' (Gioia et al., 2013; parent version, teacher version), which is a behavioural evaluation inventory of executive functions completed by parents and teachers and which makes it possible to determine whether the child has, for example, difficulties with organisation, planning or behavioural regulation.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The PEDS-QL quality of life
Description: The PEDS-QL quality of life (Tessier et al., 2009) that will be completed by the parents and the patient concerns the day to- day functioning of the child (in school, relationships to others, physical abilities and emotional state).
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort)
Description: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort) which assesses fatigue in everyday life.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The Family Functioning Inventory FAD)
Description: The Family Functioning Inventory FAD (Speranza et al., 2006) is used to assess the family functioning of the child and his/her family. The short version is used as an indicator of general functioning.
Study NCT03609112 — intervention group
Intervention type: OTHER
Intervention: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)
Description: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
Study NCT05473949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Description: use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study NCT02126579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.
Study NCT03298009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Description: 2-week intervention
Study NCT03298009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 2-week intervention
Study NCT03298009 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging
Description: 1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
Study NCT03298009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: 1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
Study NCT01802372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO CVD risk assessment package
Description: Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
Study NCT01802372 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Insurance only
Description: Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
Study NCT01374542 — intervention group
Intervention type: PROCEDURE
Intervention: Respiratory endoscopy
Description: Bronchoscopy, thoracoscopy, endobronchial ultrasound
Study NCT03088267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphetamine extended-release oral suspension, 2.5 mg/mL
Description: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Study NCT03088267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amphetamine extended-release oral suspension, 2.5 mg/mL
Description: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Study NCT03088267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo extended-release oral suspension
Description: 6, 7 or 8 mL PO
Study NCT03088267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo extended-release oral suspension
Description: 6, 7 or 8 mL PO
Study NCT01508429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 placebo tablets (resembling misoprostol) administered sublingually
Study NCT01508429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 800mcg misoprostol (4 200mcg tablets administered sublingually)
Study NCT01782066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEN-ACYW135 reduced-dose intradermal administration
Description: Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
Study NCT04278118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy
Study NCT04278118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy
Study NCT04278118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy
Study NCT04278118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04278118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00507000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
Study NCT00507000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose granules
Description: Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study NCT02554968 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Study NCT03508648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTx-024
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Study NCT03508648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Study NCT03977519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MA
Description: Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
Study NCT03977519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
Study NCT00743366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marijuana
Description: 0,6.2% THC
Study NCT00743366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: 0,6.2% THC
Study NCT00743366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 200 mg/day
Study NCT00743366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT02137161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone+Tobramycin eye drop
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
Study NCT02137161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+Tobramycin eye drop
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
Study NCT02137161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac eye drop
Description: bromfenac ophthalmic solution 0.09%
Study NCT02739282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic therapeutic drug monitoring
Description: Blood samples with antiepileptic drug level measurement
Study NCT02332590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study NCT02332590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study NCT02332590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study NCT02332590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for adalimumab)
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study NCT02446158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
Study NCT02063126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReConnect (NADH plus CoQ10)
Description: ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)
Study NCT02063126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)